< Back to previous page

Publication

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

Journal Contribution - Journal Article

Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.
Journal: GYNECOLOGIC ONCOLOGY
ISSN: 0090-8258
Issue: 2
Volume: 141
Pages: 386 - 401
Publication year:2016
BOF-keylabel:yes
IOF-keylabel:yes
BOF-publication weight:6
CSS-citation score:1
Authors:International
Authors from:Government, Higher Education
Accessibility:Closed